Trupanion (TRUP) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Trupanion (TRUP) has outperformed Veracyte (VCYT) over the past year, losing 0.9% versus a loss of 42.9%. Over five years, VCYT leads with a -39.5% price change compared with -72.0% for TRUP. Veracyte is the larger company by market cap ($2.03 billion vs $1.54 billion), about 1.3 times the size.
On valuation, Trupanion trades at a lower forward P/E (8.1x vs 16.2x for Veracyte). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus 1.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRUP | VCYT |
|---|---|---|
| Share price | $35.56 | $25.13 |
| Market cap | $1.54B | $2.03B |
| 1-day change | -0.86% | +0.36% |
| YTD return | -4.84% | -40.31% |
| 1-year return | -0.95% | -42.90% |
| 5-year return | -71.95% | -39.53% |
| P/E ratio (TTM) | 58.30 | 16.32 |
| Forward P/E | 8.14 | 16.15 |
| EPS (TTM) | $0.61 | $1.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.44B | $517.14M |
| Revenue growth (YoY) | +11.95% | +16.01% |
| Net income (latest FY) | $19.43M | $66.35M |
| Gross margin | 16.05% | 70.10% |
| Operating margin | 0.96% | 11.17% |
| Net margin | 1.35% | 12.83% |
| 52-week high | $38.87 | $60.91 |
| 52-week low | $21.16 | $21.91 |
| Distance from 52-week high | -8.52% | -58.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.35% | +77.48% |
| Average volume | 443.82K | 1.89M |
| Shares outstanding | 43.26M | 80.70M |
| Employees | 1,121 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRUP has outperformed VCYT by 42.0 percentage points over the past year.
- Trupanion trades at a higher earnings multiple (58.3x vs 16.3x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus 1.4 cents for Trupanion.
About Trupanion
TRUP stock →Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, and Continental Europe. The company operates in two segments, Subscription Business and Other Business.
Health Care · Medical Specialities · 1,121 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
TRUP vs VCYT FAQ
Which is bigger, Trupanion or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $2.03B compared with $1.54B for Trupanion (TRUP).
Which stock has performed better over the past year, TRUP or VCYT?
TRUP returned -0.95% over the past 12 months, compared with -42.90% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, TRUP or VCYT?
VCYT has the lower trailing P/E at 16.3, versus 58.3 for TRUP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Trupanion and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.